Vol 11, Supplement 1 (January 25, 2019): Journal of Thoracic Disease (Advances in Theranostic Biomarkers for Lung Cancer: from Clinical to Molecular Pathology)

Preface

Advances in theranostic biomarkers for lung cancer from clinical to molecular pathology

Paul Hofman

PDF Pages: S1-S2 Full Text (1131) Open Access

Review Article

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

Christina Alidousty, Till Baar, Carina Heydt, Svenja Wagener-Ryczek, Anna Kron, Juergen Wolf, Reinhard Buettner, Anne Maria Schultheis

PDF Pages: S3-S8 Full Text (1921) Open Access

Mesenchymal tumors of the lung: diagnostic pathology, molecular pathogenesis, and identified biomarkers

Hirotsugu Hashimoto, Yuta Tsugeno, Keisuke Sugita, Kentaro Inamura

PDF Pages: S9-S24 Full Text (12110) Open Access

Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update

Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart

PDF Pages: S25-S36 Full Text (6182) Open Access

Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation

Teodora Radonic, Chris Dickhoff, Mari Mino-Kenudson, Rutger Lely, Rick Paul, Erik Thunnissen

PDF Pages: S37-S44 Full Text (3121) Open Access

Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies

Patrycja Pawlikowska, Vincent Faugeroux, Marianne Oulhen, Agathe Aberlenc, Tala Tayoun, Emma Pailler, Françoise Farace

PDF Pages: S45-S56 Full Text (3492) Open Access

The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients

Paul Hofman

PDF Pages: S57-S64 Full Text (3470) Open Access

Resistances to EGFR tyrosine kinase inhibitors in lung cancer— how to routinely track them in a molecular pathology laboratory?

Véronique Hofman, Paul Hofman

PDF Pages: S65-S70 Full Text (1581) Open Access

Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors

Léa Berland, Simon Heeke, Olivier Humbert, Adam Macocco, Elodie Long-Mira, Sandra Lassalle, Virginie Lespinet-Fabre, Salomé Lalvée, Olivier Bordone, Charlotte Cohen, Sylvie Leroy, Véronique Hofman, Paul Hofman, Marius Ilié

PDF Pages: S71-S80 Full Text (4054) Open Access

Update on emerging biomarkers in lung cancer

Eric H. Bernicker, Timothy Craig Allen, Phillip T. Cagle

PDF Pages: S81-S88 Full Text (2622) Open Access

Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma

Sylvie Lantuejoul, Diane Damotte, Véronique Hofman, Julien Adam

PDF Pages: S89-S101 Full Text (5725) Open Access

Are there any theranostic biomarkers in small cell lung carcinoma?

Federica Pezzuto, Francesco Fortarezza, Francesca Lunardi, Fiorella Calabrese

PDF Pages: S102-S112 Full Text (2768) Open Access

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives

Guillaume Herbreteau, Audrey Vallée, Sandrine Charpentier, Nicola Normanno, Paul Hofman, Marc G. Denis

PDF Pages: S113-S126 Full Text (5834) Open Access

Disclosure:

The supplement “Advances in Theranostic Biomarkers for Lung Cancer: from Clinical to Molecular Pathology” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Paul Hofman served as the unpaid Guest Editor for the supplement.